Results 241 to 250 of about 44,405 (256)

Progressive supranuclear palsy often develops idiopathic normal pressure hydrocephalus‐like magnetic resonance imaging features

European Journal of Neurology, 2020
Idiopathic normal pressure hydrocephalus (iNPH) is a clinical entity without established pathological hallmarks. Previous autopsy studies reported that patients with an antemortem diagnosis of iNPH had a different postmortem diagnosis, commonly ...
M. Ôhara, T. Hattori, T. Yokota
semanticscholar   +1 more source

Vascular progressive supranuclear palsy

1994
Progressive supranuclear palsy (PSP) is a neurologic syndrome of unknown cause. This idiopathic type of PSP is usually associated with characteristic clinical and pathological features.To assess evidence of cerebrovascular disease in a population of patients with clinically defined PSP, and to compare clinical and neuroimaging features in vascular ...
J, Winikates, J, Jankovic
openaire   +2 more sources

Midbrain MRI assessments in progressive supranuclear palsy subtypes

Journal of Neurology Neurosurgery & Psychiatry, 2019
Objectives To explore the role of the available midbrain-based MRI morphometric assessments in (1) differentiating among progressive supranuclear palsy (PSP) subtypes (PSP Richardson’s syndrome (PSP-RS), PSP with predominant parkinsonism (PSP-P) and the ...
M. Picillo, M. F. Tepedino, F. Abate, R. Erro, S. Ponticorvo, S. Tartaglione, G. Volpe, D. Frosini, P. Cecchi, M. Cosottini, R. Ceravolo, F. Esposito, M. T. Pellecchia, P. Barone, R. Manara   +14 more
semanticscholar   +1 more source

Evolving concepts in progressive supranuclear palsy and other 4-repeat tauopathies

Nature Reviews Neurology, 2021
M. Stamelou, G. Respondek, Nikolaos Giagkou, J. Whitwell, G. Kovacs, Günter U. Höglinger   +5 more
semanticscholar   +1 more source

Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial

Nature Medicine, 2021
T. Dam, A. Boxer, L. Golbe, Günter U. Höglinger, H. Morris, I. Litvan, A. Lang, J. Corvol, I. Aiba, M. Grundman, Lili Yang, Beth Tidemann-Miller, J. Kupferman, K. Harper, Kubra Kamisoglu, M. Wald, Danielle L. Graham, L. Gedney, J. O’Gorman, S. Haeberlein   +19 more
semanticscholar   +1 more source

[Progressive supranuclear palsy].

Rinsho shinkeigaku = Clinical neurology, 1998
Progressive supranuclear paly (PSP) was firstly reported by Steel in 1964. This condition was separated from Parkinsonism by both clinical symptoms and neuropathological findings. Recently, in an attempt to improve diagnostic accuracy to give appropriate informed concepts and to select correct cases for drug studies or other research purpose ...
openaire   +3 more sources

Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome)

Neurology, 1996
I. Litvan, Y. Agid, D. Calne, G. Campbell, B. Dubois, R. Duvoisin, C. Goetz, L. Golbe, J. Grafman, J. Growdon, M. Hallett, J. Jankovic, N. Quinn, E. Tolosa, D. Zee   +14 more
semanticscholar   +1 more source

Gender differences in progressive supranuclear palsy

Acta Neurologica Belgica, 2021
R. Mahale, Syam Krishnan, K. Divya, V. T. Jisha, A. Kishore   +4 more
semanticscholar   +1 more source

[Progressive supranuclear palsy].

Schweizerische Rundschau fur Medizin Praxis = Revue suisse de medecine Praxis, 1993
Progressive supranuclear palsy, first described as clinical entity by Steele, Richardson and Olszewski, is a degenerative disorder of the central nervous system. Besides progressive supranuclear oculomotor disturbances, other characteristic signs are pseudobulbar paresis, axial rigidity, gait disturbances and subcortical dementia.
openaire   +1 more source

Progressive supranuclear palsy

2011
Andrew E. Budson, Paul R. Solomon
openaire   +2 more sources